Drug may help melanoma patients survive longer
RESEARCHERS have scored the first big win against melanoma, the deadliest form of skin cancer. An experimental drug significantly improved survival in a major study of people with very advanced disease.
The results, reported on Saturday at a cancer conference, left doctors elated.
"We have not had any therapy that has prolonged survival" until now, said Lynn Schuchter of the Abramson Cancer Center at the University of Pennsylvania, a skin cancer specialist with no role in the study or ties to the drug's maker.
The drug, ipilimumab, (ip-ee-LIM-uh-mab), works by helping the immune system fight tumors. The United States Food and Drug Administration has pledged a quick review, and doctors think the drug could be available by the end of this year.
"People are going to have a lot of hope and want this drug, and it's not on their doctors' shelves," although some may be able to get it through special programs directly from its maker, Bristol-Myers Squibb Co, Schuchter said.
Melanoma is the most serious form of skin cancer. Last year in the US, there were about 68,720 new cases and 8,650 deaths from the disease. Worldwide, more than 50,000 people die of melanoma each year.
"The incidence is rising faster than any other cancer," said one of the study's leaders, Stephen Hodi of Dana-Farber Cancer Institute in Boston. "When it spreads to vital organs, it's almost always fatal."
The study involved 676 people globally with advanced, inoperable melanoma who had already tried other treatments. They were given one of three treatments: ipilimumab by itself, with another immune-stimulating treatment, or the immune-stimulating treatment alone.
After two years, 24 percent of those given the drug alone or in combination were alive, versus 14 percent of those given just the immune-stimulating treatment.
The results, reported on Saturday at a cancer conference, left doctors elated.
"We have not had any therapy that has prolonged survival" until now, said Lynn Schuchter of the Abramson Cancer Center at the University of Pennsylvania, a skin cancer specialist with no role in the study or ties to the drug's maker.
The drug, ipilimumab, (ip-ee-LIM-uh-mab), works by helping the immune system fight tumors. The United States Food and Drug Administration has pledged a quick review, and doctors think the drug could be available by the end of this year.
"People are going to have a lot of hope and want this drug, and it's not on their doctors' shelves," although some may be able to get it through special programs directly from its maker, Bristol-Myers Squibb Co, Schuchter said.
Melanoma is the most serious form of skin cancer. Last year in the US, there were about 68,720 new cases and 8,650 deaths from the disease. Worldwide, more than 50,000 people die of melanoma each year.
"The incidence is rising faster than any other cancer," said one of the study's leaders, Stephen Hodi of Dana-Farber Cancer Institute in Boston. "When it spreads to vital organs, it's almost always fatal."
The study involved 676 people globally with advanced, inoperable melanoma who had already tried other treatments. They were given one of three treatments: ipilimumab by itself, with another immune-stimulating treatment, or the immune-stimulating treatment alone.
After two years, 24 percent of those given the drug alone or in combination were alive, versus 14 percent of those given just the immune-stimulating treatment.
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔$粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.